deltatrials
Completed PHASE1 INTERVENTIONAL 1-arm NCT02133742

A Dose Finding Study To Evaluate Safety, Drug Interaction, Tumor Markers Of Axitinib In Combination With MK-3475 In Adult Patients With Previously Untreated Advanced Renal Cell Cancer

A PHASE 1B, OPEN LABEL, DOSE FINDING STUDY TO EVALUATE SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF AXITINIB (AG-013736) IN COMBINATION WITH PEMBROLIZUMAB (MK-3475) IN PATIENTS WITH ADVANCED RENAL CELL CANCER

Sponsor: Merck Sharp & Dohme LLC

Conditions Renal Cell Carcinoma
Interventions Axitinib MK-3475
Updated 19 times since 2017 Last updated: Jul 26, 2021 Started: Sep 16, 2014 Primary completion: Mar 31, 2017 Completion: Jul 3, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Renal Cell Carcinoma, this trial is completed. The trial is conducted by Merck Sharp & Dohme LLC and has accumulated 19 data snapshots since 2014. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jun 2017 · 4 months · monthly snapshot~Jun 2017 – ~Aug 2017 · 2 months · monthly snapshot~Aug 2017 – ~Jan 2018 · 5 months · monthly snapshot~Jan 2018 – ~Jun 2018 · 5 months · monthly snapshot~Jun 2018 – ~Jul 2019 · 13 months · monthly snapshot~Jul 2019 – ~Sep 2019 · 2 months · monthly snapshot~Sep 2019 – ~Oct 2019 · 30 days · monthly snapshot~Oct 2019 – ~Mar 2020 · 5 months · monthly snapshot~Mar 2020 – ~Apr 2020 · 31 days · monthly snapshot~Apr 2020 – ~Aug 2020 · 4 months · monthly snapshot~Aug 2020 – ~Jan 2021 · 5 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Jun 2022 · 9 months · monthly snapshot~Jun 2022 – ~Jul 2024 · 25 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 7 months · monthly snapshot~Jan 2026 – present · 3 months · monthly snapshot

Change History

19 versions recorded

  1. Jan 2026 — Present [monthly]

    Completed PHASE1

  2. Sep 2025 — Present [monthly]

    Completed PHASE1

  3. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE1

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  5. Jun 2022 — Jul 2024 [monthly]

    Completed PHASE1

▶ Show 14 earlier versions

  1. Sep 2021 — Jun 2022 [monthly]

    Completed PHASE1

  2. Jan 2021 — Sep 2021 [monthly]

    Completed PHASE1

  3. Aug 2020 — Jan 2021 [monthly]

    Completed PHASE1

  4. Apr 2020 — Aug 2020 [monthly]

    Completed PHASE1

  5. Mar 2020 — Apr 2020 [monthly]

    Completed PHASE1

  6. Oct 2019 — Mar 2020 [monthly]

    Completed PHASE1

  7. Sep 2019 — Oct 2019 [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

  8. Jul 2019 — Sep 2019 [monthly]

    Active Not Recruiting PHASE1

  9. Jun 2018 — Jul 2019 [monthly]

    Active Not Recruiting PHASE1

  10. Jan 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE1

  11. Aug 2017 — Jan 2018 [monthly]

    Active Not Recruiting PHASE1

  12. Jun 2017 — Aug 2017 [monthly]

    Active Not Recruiting PHASE1

  13. Feb 2017 — Jun 2017 [monthly]

    Active Not Recruiting PHASE1

  14. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE1

    First recorded

Sep 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Merck Sharp & Dohme LLC
  • Pfizer
Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations